studies

334A AASLD ABSTRACTS HEPATOLOGY, October, 2015
Comparing two combination therapies, Arm A achieved higher
rates of HBsAg loss (P=0.016) following flares than Arm B.
This is partly driven by HBeAg-negative patients in Arm A who
attained disproportionately increasing rates of HBsAg loss and
HBsAg decline ≥ 1log 10
IU/ml which was not observed in
Arm B. Conclusion: Treatment-associated ALT flares, especially
with TDF+PEG combination therapy, are associated with clinical
endpoints related to HBV immune control. ALT flares were
higher in the TDF+PEG x48w group and associated with the
highest HBsAg loss.
Table: Proportion of Patients who Achieved Clinical Endpoints by
ALT flare status (N=679)
*Includes subjects with baseline HBeAg-positive only.
Disclosures:
Henry Lik-Yuen Chan - Advisory Committees or Review Panels: Gilead, MSD,
Bristol-Myers Squibb, Roche, Novartis Pharmaceutical, Abbvie; Speaking and
Teaching: Echosens
Wan-Long Chuang - Advisory Committees or Review Panels: Gilead, Abbvie;
Speaking and Teaching: BMS, Roche, MSD
Joerg Petersen - Advisory Committees or Review Panels: Bristol-Myers Squibb,
Gilead, Novartis, Merck, Bristol-Myers Squibb, Gilead, Novartis, Merck; Grant/
Research Support: Roche, GlaxoSmithKline, Roche, GlaxoSmithKline; Speaking
and Teaching: Abbott, Tibotec, Merck, Abbott, Tibotec, Merck
Phillip Dinh - Employment: Gilead Sciences; Stock Shareholder: Gilead Sciences
Eduardo B. Martins - Employment: Gilead Sciences, Inc.; Stock Shareholder:
Gilead Sciences, Inc.
Leland J. Yee - Employment: Gilead Science
Prista Charuworn - Stock Shareholder: Gilead Sciences
Mani Subramanian - Employment: Gilead Sciences
Harry L. Janssen - Consulting: AbbVie, Bristol Myers Squibb, GSK, Gilead Sciences,
Innogenetics, Merck, Medtronic, Novartis, Roche, Janssen, Medimmune,
ISIS Pharmaceuticals, Tekmira; Grant/Research Support: AbbVie, Bristol Myers
Squibb, Gilead Sciences, Innogenetics, Merck, Medtronic, Novartis, Roche,
Janssen, Medimmune
Seng Gee Lim - Advisory Committees or Review Panels: Bristol-Myers Squibb,
Novartis Pharmaceuticals, Merck Sharp and Dohme Pharmaceuticals, Gilead
Pharmaceuticals, Roche Pharmaceuticals; Speaking and Teaching: Bristol-Myers
Squibb, Novartis Pharmaceuticals, Merck Sharp and Dohme Pharmaceuticals,
Gilead Pharmaceuticals
Scott Fung - Advisory Committees or Review Panels: Gilead Sciences, Merck,
Vertex, Roche; Speaking and Teaching: BMS, Gilead, AbbVie, Janssen, Merck
Graham R. Foster - Advisory Committees or Review Panels: GlaxoSmithKline,
Novartis, Boehringer Ingelheim, Tibotec, Chughai, Gilead, Janssen, Idenix,
GlaxoSmithKline, Novartis, Roche, Tibotec, Chughai, Gilead, Merck, Janssen,
Idenix, BMS; Board Membership: Boehringer Ingelheim; Grant/Research Support:
Chughai, Roche, Chughai; Speaking and Teaching: Roche, Gilead, Tibotec,
Merck, BMS, Boehringer Ingelheim, Gilead, Janssen
Maria Buti - Advisory Committees or Review Panels: Gilead, Janssen, MSD;
Grant/Research Support: Gilead, Janssen; Speaking and Teaching: Gilead,
Janssen, BMS
Giovanni B. Gaeta - Advisory Committees or Review Panels: Janssen, Merck,
Abbvie, Roche; Speaking and Teaching: BMS, Gilead
George V. Papatheodoridis - Advisory Committees or Review Panels: Merck
Sharp & Dohme, Novartis, Abbvie, Boerhinger Ingelheim, Bristol-Meyer Squibb,
Gilead, Roche, Janssen, GlaxoSmith Kleine; Grant/Research Support: Roche,
Gilead, Bristol-Meyer Squibb, Abbvie, Janssen; Speaking and Teaching: Merck
Sharp & Dohme, Bristol-Meyer Squibb, Gilead, Roche, Janssen, Abbvie
Robert Flisiak - Advisory Committees or Review Panels: Gilead, Bristol Myers
Squibb, Janssen, Merck, Roche, Abbvie; Consulting: Janssen, Bristol Myers
Squibb, Gilead, Merck, Abbvie; Grant/Research Support: Roche; Speaking and
Teaching: Janssen, Roche, Bristol Myers Squibb, Gilead, Merck, Abbvie
Patrick Marcellin - Consulting: Roche, Gilead, BMS, Vertex, Novartis, Janssen,
MSD, Abbvie, Alios BioPharma, Idenix, Akron; Grant/Research Support: Roche,
Gilead, BMS, Novartis, Janssen, MSD, Alios BioPharma; Speaking and Teaching:
Roche, Gilead, BMS, Vertex, Novartis, Janssen, MSD, Boehringer, Pfizer,
Abbvie
The following authors have nothing to disclose: Sang Hoon Ahn, Fehmi Tabak,
Rajiv Mehta, Kyungpil Kim, Aric Josun Hui
242
Nucleos(t)ide Analogues against Hepatitis B Virus
Reduces the Risk of Various Major Malignancies: a
Nationwide Cohort Study Based on the Health Insurance
Review and Assessment Service Database.
Donghyeon Lee 1 , Jeong-Hoon Lee 1 , Yuri Cho 1 , Jeong-Ju Yoo 1 ,
Minjong Lee 1 , Young Youn Cho 1 , Hyeki Cho 1 , Hongkeun Ahn 1 ,
June Sung Lee 2 , Eun Ju Cho 1 , Su Jong Yu 1 , Yoon Jun Kim 1 , Jung-
Hwan Yoon 1 ; 1 Seoul national university hospital, Seoul, Korea (the
Republic of); 2 Inje University, Ilsan Paik Hospital, Ilsan, Korea (the
Republic of)
Background: Preceding epidemiology studies reported that
chronic hepatitis B virus (HBV) infection is a risk factor for various
malignancies including hepatocellular carcinoma (HCC),
cholangiocarcinoma, non-Hodgkin lymphoma, and stomach
cancer. These associations have been partially explained by
the HBV-inducing immune tolerance to malignant cells. It has
been well proven that antiviral treatment in chronic hepatitis
B (CHB) patients reduces the risk of HCC. However, it is still
unclear whether nucleos(t)ide analogues (NAs) against HBV
could reduce the risk of various malignancies except for HCC.
In this study, we evaluated the association of anti-HBV treatment
with NAs and the risk of various cancers in CHB patients.
Methods: The National Claims Database from Health Insurance
Review and Assessment Service (HIRA) was used. From
this database, we included CHB patients who received anti-
HBV NAs (i.e., lamivudine, telvibudine, clevudine, adefovir,
entecavir, and tenofovir) for > 30 days between 2009 and
2013 (the NA group) or no antiviral treatment (the control
group). Date of data cutoff was December 31, 2014. The
hazard ratio (HR) for NAs was calculated by Cox regression
model. Results: A total of 299,740 patients with CHB were
included and 39,900 patients (13.3%) were involved in the
NA group. During the study period 14,186 patients developed
any kind of malignancy. In multivariate analysis, the NA
group showed significantly lower risk of developing new malignancies
(vs the control group; HR=0.511, 95% confidence
interval=0.466-0.561, P